Clinical Trial Update: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the Medical Information Device #1 (MIND1) for adherence, safety, and tolerability in schizophrenia or Bipolar I disorder has been withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• MIND1

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Bipolar 1 Disorder, Schizophrenia | Phase 2 | Status: WITHDRAWN